Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
TAA06-UCAR-gammadeltaT by PersonGen BioTherapeutics (Suzhou) for Solid Tumor: Likelihood of Approval
TAA06-UCAR-gammadeltaT is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Solid Tumor. According to GlobalData,...